All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Clinical trial club | Luspatercept mechanism of action

Bookmark this article

On June 28, 2023, Scientific Education Support hosted a clinical trial club entitled “NCT03194542 trial:​ Luspatercept for the treatment of patients with anemic myelofibrosis.” This live webinar was part of the MPN Hub Clinical Trial Club webinar series, “Novel agents for the treatment of advanced myelofibrosis.”

The webinar reviewed the phase II NCT03194542 trial investigating luspatercept, an activin receptor ligand trap, for the treatment of anemic myelofibrosis. The event was chaired by Jean-Jacques Kiladjian, Université de Paris - Hôpital Saint-Louis, Paris, FR, who was joined by trial investigator, Aaron Gerds​, Cleveland Clinic Taussig Cancer Institute, Cleveland, US.

Kiladjian began by outlining the mechanism of action of luspatercept. He highlighted the importance of erythropoiesis, the role of TGF-β superfamily signaling, and how luspatercept reduces SMAD2/3 signaling​.


Subscribe to get the best content related to MPN delivered to your inbox